(Q50495964)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Guideline for the diagnosis and management of myelofibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Maria Gilleece

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Adam J Mead

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Mallika Sekhar

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

John T Reilly

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Mary Frances McMullin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Philip A Beer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Nauman Butt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Eibhlean Conneally

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Andrew Duncombe

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

N George Michaeel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Georgina W Hall

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Steven Knapper

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Ruben A Mesa

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Bridget Wilkins

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Claire N Harrison

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Writing group: British Committee for Standards in Haematology

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

1 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

158

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

453-471

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22651893%20AND%20SRC:MED&resulttype=core&format=json

Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Outcome of transplantation for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

How I treat essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Nutritional rickets presenting with myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

The myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

EZH2 mutational status predicts poor survival in myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Guideline for investigation and management of adults and children presenting with a thrombocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Oxymetholone treatment in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Meningeal hematopoiesis causing exophthalmus and hemiparesis in myelofibrosis: effect of radiotherapy. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Liver Dysfunction following Splenectomy in Idiopathic Myelofibrosis: A Study of 10 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Androgens and erythropoiesis: past and present

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

A patient with myelofibrosis complicated by refractory ascites and portal hypertension: to tips or not to tips? A case report with discussion of the mechanism of ascites formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Allogeneic hematopoietic cell transplantation for patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X

Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09179.X